Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α

Beatrice Macchi; Emanuela Balestrieri; Caterina Frezza; Sandro Grelli; Elena Valletta; Ambroise Marçais; Francesca Marino-Merlo; Jocelyn Turpin; Charles R Bangham; Olivier Hermine; Antonio Mastino; Ali Bazarbachi

doi:10.1182/bloodadvances.2016001370

Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α

Blood Adv. 2017 May 5;1(12):748-752. doi: 10.1182/bloodadvances.2016001370. eCollection 2017 May 9.

Authors

Beatrice Macchi¹, Emanuela Balestrieri², Caterina Frezza^{1

3}, Sandro Grelli², Elena Valletta¹, Ambroise Marçais^{4

5

6}, Francesca Marino-Merlo⁷, Jocelyn Turpin⁸, Charles R Bangham⁸, Olivier Hermine^{4

5

6}, Antonio Mastino^{3

9}, Ali Bazarbachi^{10

11}

Affiliations

¹ Department of System Medicine and.
² Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
³ Institute of Translational Pharmacology, National Research Council, Rome, Italy.
⁴ Imagine Institute, INSERM U1163, Paris, France.
⁵ Équipe de Recherche Labellisée 8654, Centre National de la Recherche Scientifique, Paris, France.
⁶ Department of Hematology, Hôpital Necker, Paris, France.
⁷ IRCCS Centro Neurolesi "Bonino Pulejo," Messina, Italy.
⁸ Section of Virology, Department of Medicine, Imperial College London, London, United Kingdom.
⁹ Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Messina, Italy; and.
¹⁰ Department of Internal Medicine and.
¹¹ Department of Anatomy, Cell Biology, and Physiological Sciences, American University of Beirut, Beirut, Lebanon.

Abstract

The therapeutic efficacy of the AZT and IFN combination in ATL presumably reflects the inhibition of RT-related functions.HTLV-1-RT activity from short-term cultured PBMCs may represent a predictive correlate of clinical response to AZT/IFN in ATL patients.